Association of microvessel density and blood vessel invasion with the prognosis in rectal carcinoma at stages I to II.
- Author:
Yong-jian ZHOU
1
;
Qin YE
;
Hui-shan LU
;
Ying-hong YANG
;
Guo-xian GUAN
;
Chang-ming HUANG
;
Chuan WANG
;
Jie ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Antigens, CD; metabolism; Antigens, CD34; metabolism; Endoglin; Female; Humans; Male; Microvessels; pathology; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; pathology; Prognosis; Receptors, Cell Surface; metabolism; Rectal Neoplasms; blood supply; diagnosis; pathology
- From: Chinese Journal of Gastrointestinal Surgery 2010;13(7):516-519
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the possibility of microvessel density (MVD) and blood vessel invade (BVI) as the indexes in predicting prognosis of rectal carcinoma at stages I to II.
METHODSTumor tissues from 380 patients who underwent resection of stage I or II rectal cancer were analyzed for MVD and BVI by immunohistochemical S-P method with anti-CD105 and anti-CD 34 antibody. Binary and multivariable Cox regression was applied to indicate independent factors associated with overall survival.
RESULTSCD105 was present in the neovascularity of the cancer tissue but not in the normal tissue, while CD34 was present in the tumor tissue and the normal tissue. BVI on CD34 staining was significantly higher than that on HE staining. Multivariable analysis revealed that TNM stage, CD34-BVI, histologic type, and CD105-MDV were independent risk factors to predict the possibility of poor prognosis of stage I or II rectal cancer. CD34-BVI or CD105-MVD positivity had a hazard ratio of 4.483 (95% confidence interval 2.861-7.026) for mortality.
CONCLUSIONThe expressions of CD34-BVI and CD105-MVD are independent factors to predict the possibility of poor survival of stage I or II rectal carcinoma. Detection of CD105-MVD combined with CD34-BVI may help predict clinical outcome and design further individualized adjuvant treatment.